Daniel  Janney net worth and biography

Daniel Janney Biography and Net Worth

Director of Allakos
Dan Janney has been investing in life sciences companies for more than 20 years. Mr. Janney joined Alta Partners at its founding and is a Managing Director. His focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 32 companies. Prior to Alta, he was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions. Mr. Janney is currently on the board of directors of several public and private companies, including Esperion Therapeutics, Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve. In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (acquired by Cephalon), CoTherix (acquired by Actelion), DeUnity Health (acquired by United Health), Dynavax, Endonetics (acquired by Medtronic), Ilex Oncology (acquired by Millennium Pharmaceuticals), InterMune (acquired by Roche), LJL Biosystems (acquired by Molecular Devices), Mako Surgical (acquired by Stryker) and Triangle Pharmaceuticals (acquired by Gilead).

In 2006 and 2007, Mr. Janney was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President’s Council of the J. David Gladstone Institutes and serves on the Board of Regents of Georgetown University. He holds a Bachelor of Arts from Georgetown University and an MBA from the Anderson School at the University of California, Los Angeles.

What is Daniel Janney's net worth?

The estimated net worth of Daniel Janney is at least $28,290.53 as of June 8th, 2023. Mr. Janney owns 126,297 shares of Allakos stock worth more than $28,291 as of April 1st. This net worth estimate does not reflect any other investments that Mr. Janney may own. Learn More about Daniel Janney's net worth.

How do I contact Daniel Janney?

The corporate mailing address for Mr. Janney and other Allakos executives is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. Allakos can also be reached via phone at (650) 597-5002 and via email at ir@allakos.com. Learn More on Daniel Janney's contact information.

Has Daniel Janney been buying or selling shares of Allakos?

Daniel Janney has not been actively trading shares of Allakos during the last ninety days. Most recently, Daniel Janney sold 17,308 shares of the business's stock in a transaction on Friday, March 26th. The shares were sold at an average price of $115.17, for a transaction totalling $1,993,362.36. Learn More on Daniel Janney's trading history.

Who are Allakos' active insiders?

Allakos' insider roster includes Robert Alexander (CEO), Peter Hudson (Major Shareholder), Steven James (Director), Daniel Janney (Director), Robert More (Major Shareholder), Henrik Rassmussen (Insider), and Adam Tomasi (COO). Learn More on Allakos' active insiders.

Are insiders buying or selling shares of Allakos?

During the last twelve months, insiders at the sold shares 1 times. They sold a total of 87,064 shares worth more than $87,934.64. The most recent insider tranaction occured on June, 28th when CFO Harlan Baird Radford sold 87,064 shares worth more than $87,934.64. Insiders at Allakos own 16.1% of the company. Learn More about insider trades at Allakos.

Information on this page was last updated on 6/28/2024.

Daniel Janney Insider Trading History at Allakos

See Full Table

Daniel Janney Buying and Selling Activity at Allakos

This chart shows Daniel Janney's buying and selling at Allakos by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2$0Total Insider BuyingTotal Insider Selling

Allakos Company Overview

Allakos logo
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $0.22
Low: $0.22
High: $0.23

50 Day Range

MA: $0.33
Low: $0.23
High: $1.21

2 Week Range

Now: $0.22
Low: $0.22
High: $1.56

Volume

434,449 shs

Average Volume

2,397,432 shs

Market Capitalization

$19.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72